{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:08Z","timestamp":1792723088432,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.09.014","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:52:26Z","timestamp":1792720346000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Platelet Therapeutics"],"prefix":"10.1016","author":[{"given":"Marie","family":"Scully","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Paul","family":"Westwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Howells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.hoc.2026.09.014_bib1","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2026.09.014_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101300","article-title":"The new era of primary immune thrombocytopenia management in adults: a narrative review of current and emerging treatments","volume":"73","author":"Gonz\u00e1lez-L\u00f3pez","year":"2025","journal-title":"Blood Rev"},{"key":"10.1016\/j.hoc.2026.09.014_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101112","article-title":"Primary and secondary immune thrombocytopenia (ITP): time for a rethink","volume":"61","author":"Gonz\u00e1lez-L\u00f3pez","year":"2023","journal-title":"Blood Rev"},{"issue":"23","key":"10.1016\/j.hoc.2026.09.014_bib4","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American society of hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.014_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.26036","article-title":"Immune thrombocytopenia (ITP) world impact survey (I-WISh): impact of ITP on health-related quality of life","volume":"96","author":"Cooper","year":"2021","journal-title":"Am J Hematol"},{"issue":"9610","key":"10.1016\/j.hoc.2026.09.014_bib6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.014_bib7","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.014_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2026.09.014_bib9","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.014_bib10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.014_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3892\/br.2024.1732","article-title":"Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Shen","year":"2024","journal-title":"Biomed Rep"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.014_bib12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2013.098921","article-title":"Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up","volume":"99","author":"Ghanima","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2026.09.014_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719837906","article-title":"Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia","volume":"10","author":"Gonz\u00e1lez-Porras","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2026.09.014_bib14","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/bjh.19345","article-title":"Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: results from the TRAIT study","volume":"204","author":"Cooper","year":"2024","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.hoc.2026.09.014_bib15","first-page":"2867","article-title":"Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study","volume":"141","author":"Guillet","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2026.09.014_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100647","article-title":"Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: real-World recommendations","volume":"41","author":"Zaja","year":"2020","journal-title":"Blood Rev"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.014_bib17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.014_bib18","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program","volume":"94","author":"Bussel","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2026.09.014_bib19","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(23)00034-0","article-title":"Sovleplenib (HMPL-523), a novel syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b\/2 study","volume":"10","author":"Liu","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.014_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cei\/uxac096","article-title":"A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models","volume":"211","author":"Cho","year":"2023","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.014_bib21","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.014_bib22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"issue":"9978","key":"10.1016\/j.hoc.2026.09.014_bib23","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.hoc.2026.09.014_bib24","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux","volume":"94","author":"Deshayes","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.014_bib25","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.3324\/haematol.2014.110213","article-title":"Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients","volume":"100","author":"Zwaginga","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.014_bib26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2141.2012.09169.x","article-title":"Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis","volume":"158","author":"Auger","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.014_bib27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.14782","article-title":"GPIIb\/IIIa autoantibody predicts better rituximab response in ITP","volume":"182","author":"Feng","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.014_bib28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.21512","article-title":"Repeated courses of rituximab in chronic ITP: three different regimens","volume":"84","author":"Hasan","year":"2009","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.014_bib29","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.23518","article-title":"Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia","volume":"88","author":"Mah\u00e9vas","year":"2013","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2026.09.014_bib30","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3324\/haematol.12206","article-title":"Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura","volume":"93","author":"Zaja","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.014_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2023.2200848","article-title":"Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study","volume":"34","author":"Mageau","year":"2023","journal-title":"Platelets"},{"issue":"22","key":"10.1016\/j.hoc.2026.09.014_bib32","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.014_bib33","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"Chugh","year":"2015","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.014_bib34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.13622","article-title":"Mycophenolate mofetil therapy for severe immune thrombocytopenia","volume":"171","author":"Taylor","year":"2015","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.014_bib35","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.014_bib36","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10067-023-06820-4","article-title":"Efficacy and safety of mycophenolate mofetil in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis","volume":"43","author":"Abdelwahab","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.hoc.2026.09.014_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1415389","article-title":"Infection risk in patients with autoimmune cytopenias and immune dysregulation treated with mycophenolate mofetil and sirolimus","volume":"15","author":"Comella","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.014_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2024.100035","article-title":"Role of azathioprine in the management of ITP in the TPO-RA era: a single-center retrospective study","volume":"2","author":"Le-Nguyen","year":"2025","journal-title":"Blood Vessel Thromb Hemost"},{"key":"10.1016\/j.hoc.2026.09.014_bib39","first-page":"1451","article-title":"Verschwinden der h\u00e4morrhagischen diathese bei einem fall von \u201cessentieller thrombopenie\u201d (frank) nach milzexstirpation: splenogene thrombolytische purpura","volume":"29","author":"P","year":"2016","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.014_bib40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.19077","article-title":"Is splenectomy a good strategy for refractory immune thrombocytopenia in adults?","volume":"203","author":"Godeau","year":"2023","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.hoc.2026.09.014_bib41","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1182\/blood-2012-12-467068","article-title":"Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia","volume":"121","author":"Boyle","year":"2013","journal-title":"Blood"},{"issue":"48","key":"10.1016\/j.hoc.2026.09.014_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005098","article-title":"Long-term complications of splenectomy in adult immune thrombocytopenia","volume":"95","author":"Thai","year":"2016","journal-title":"Medicine (Baltim)"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.014_bib43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2010.08377.x","article-title":"Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP registry","volume":"151","author":"Sarpatwari","year":"2010","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.hoc.2026.09.014_bib44","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2026.09.014_bib45","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/bjh.16327","article-title":"Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia","volume":"189","author":"Zhang","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2026.09.014_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101777","article-title":"Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: a systematic review and network meta-analysis","volume":"56","author":"Wang","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.014_bib47","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(21)00030-2","article-title":"Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial","volume":"8","author":"Sun","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.014_bib48","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3026(21)00240-4","article-title":"All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"8","author":"Huang","year":"2021","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2026.09.014_bib49","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1182\/blood-2016-03-704734","article-title":"Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia","volume":"128","author":"Mah\u00e9vas","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.014_bib50","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/bjh.19602","article-title":"Avatrombopag plus fostamatinib combination as treatment in patients with multirefractory immune thrombocytopenia","volume":"205","author":"Mingot-Castellano","year":"2024","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.014_bib51","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/bjh.18893","article-title":"Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience","volume":"202","author":"Crickx","year":"2023","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2026.09.014_bib52","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood.V97.9.2549","article-title":"Morbidity and mortality in adults with idiopathic thrombocytopenic purpura","volume":"97","author":"Portielje","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.014_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.19075","article-title":"Refractory immune thrombocytopenia in adults: towards a new definition","volume":"203","author":"Arnold","year":"2023","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.014_bib54","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood.2019003599","article-title":"Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment","volume":"135","author":"Miltiadous","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2026.09.014_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.863177","article-title":"Case report: use of obinutuzumab as an alternative monoclonal Anti-CD20 antibody in a patient with refractory immune thrombocytopenia complicated by rituximab-induced serum sickness and anti-rituximab antibodies","volume":"13","author":"Blase","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.014_bib56","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/bjh.17105","article-title":"Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma","volume":"192","author":"Herishanu","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2026.09.014_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2023.102724","article-title":"Daratumumab as a novel treatment option in refractory ITP","volume":"99","author":"Vernava","year":"2023","journal-title":"Blood Cells Mol Dis"},{"issue":"14","key":"10.1016\/j.hoc.2026.09.014_bib58","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1056\/NEJMoa2513120","article-title":"A phase 2 randomized trial of mezagitamab in primary immune thrombocytopenia","volume":"394","author":"Kuter","year":"2026","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.hoc.2026.09.014_bib59","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2017-06-789578","article-title":"BAFF and CD4(+) T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context","volume":"131","author":"Thai","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2026.09.014_bib60","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3324\/haematol.2020.259481","article-title":"Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial","volume":"106","author":"Mah\u00e9vas","year":"2021","journal-title":"Haematologica"},{"issue":"10320","key":"10.1016\/j.hoc.2026.09.014_bib61","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary sj\u00f6gren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.014_bib62","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2024-201418","article-title":"A phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy: interim results from VAYHIT3","volume":"144","author":"Kuter","year":"2024","journal-title":"Blood"},{"issue":"10413","key":"10.1016\/j.hoc.2026.09.014_bib63","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.hoc.2026.09.014_bib64","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.09.014_bib65","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231205431","article-title":"Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study","volume":"14","author":"Kuter","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"10.1016\/j.hoc.2026.09.014_bib66","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/bloodadvances.2021006864","article-title":"Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia","volume":"7","author":"Broome","year":"2023","journal-title":"Blood Adv"},{"issue":"10472","key":"10.1016\/j.hoc.2026.09.014_bib67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(24)02504-2","article-title":"Salvage treatment of multi-refractory primary immune thrombocytopenia with CD19 CAR T cells","volume":"405","author":"Trautmann-Grill","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.014_bib68","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ejh.13803","article-title":"Incidence of adult primary immune thrombocytopenia in England-An update","volume":"109","author":"Doobaree","year":"2022","journal-title":"Eur J Haematol"},{"issue":"22","key":"10.1016\/j.hoc.2026.09.014_bib69","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.014_bib70","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood.2021010735","article-title":"Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia","volume":"138","author":"Palandri","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2026.09.014_bib71","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/bjh.14564","article-title":"Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond","volume":"177","author":"Taylor","year":"2017","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2026.09.014_bib72","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.2025.7529","article-title":"Platelet transfusion: 2025 AABB and ICTMG international clinical practice guidelines","volume":"334","author":"Metcalf","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.014_bib73","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/hematology.2024000595","article-title":"ITP in pregnancy: diagnostics and therapeutics in 2024","volume":"2024","author":"Fogerty","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"10.1016\/j.hoc.2026.09.014_bib74","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2016-04-710285","article-title":"Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy","volume":"128","author":"Sun","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2026.09.014_bib75","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.bja.2021.03.024","article-title":"Obstetric neuraxial anaesthesia in the setting of immune thrombocytopenia and low platelet counts: call to participate in an international registry","volume":"127","author":"Malinowski","year":"2021","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.hoc.2026.09.014_bib76","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211001139","article-title":"Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review","volume":"12","author":"Agarwal","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"10.1016\/j.hoc.2026.09.014_bib77","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/bjh.19161","article-title":"Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists","volume":"203","author":"Rottenstreich","year":"2023","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2026.09.014_bib78","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/1753495X18778489","article-title":"Rituximab - a novel therapy for severe ITP in pregnancy: a case report","volume":"12","author":"Donohoe","year":"2019","journal-title":"Obstet Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:52:34Z","timestamp":1792720354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826001243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":78,"alternative-id":["S0889858826001243"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.09.014","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}